Adnexus Therapeutics

Adnexus Therapeutics Announces Presentation of Interim Phase I Results for CT-322, First Adnectin Therapeutic in Humans

Adnexus Therapeutics Announces Presentation of Interim Phase I Results for CT-322, First Adnectin Therapeutic in Humans

February 2, 2007

Angiogenesis Inhibitor, CT-322, Shows Biological Activity at First Dose Level Tested

Helicos BioSciences Corporation

Helicos BioSciences Announces a Novel Homopolymer Solution for True Single Molecule Sequencing (tSMS™)

Helicos BioSciences Announces a Novel Homopolymer Solution for True Single Molecule Sequencing (tSMS™)

February 9, 2007

The company’s researchers have developed proprietary nucleotide-polymerase formulations that enable sequencing through homopolymers.

VisEn Medical, Inc.

Industry Veteran Erik Wallden Joins VisEn Medical Board of Directors

Industry Veteran Erik Wallden Joins VisEn Medical Board of Directors

February 8, 2007

Woburn, MA (February 8, 2007) -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, today announced that Erik Wallden has joined the company’s Board of Directors. Previously, Mr. Wallden served as the President and CEO of Biacore International AB, which was sold after a successful turnaround to GE Healthcare in September, 2006.

Epitome Biosystems

Epitome Biosystems Expands Senior Management Team

Epitome Biosystems Expands Senior Management Team

February 13, 2007

Jeffrey Radding Draws on Pharmaceutical Experience to Lead Research and Development

Waltham, MA, February 13, 2007 – Epitome Biosystems, a biotechnology company focused on innovative protein measurement systems, announced today the appointment of Jeffrey Radding, Ph.D., as Vice President, Research & Development. Dr. Radding joins the Company from Eli Lilly, where he led the Platform Biology Group in evaluating and implementing cell signaling approaches for drug discovery across multiple therapeutic areas.

Mascoma Corporation

Flagship Highlighted in CNBC Article on Green Technology

Flagship Highlighted in CNBC Article on Green Technology

February 13, 2007

Flagship General Partner Jim Matheson was recently interviewed and quoted in a CNBC web article about Venture Capital invesment in technolgies for alternative energy, which also highlights portfolio company Mascoma.

Green Technology Revs Up Venture Capitalists
By Scott Reeves | 13 Feb 2007 | 03:09 PM
cnbc.com

© 2007 CNBC, Inc. All Rights Reserved

The smart money sees a green future in alternative technology.

Black Duck Software, Inc.

Black Duck Software Closes $12 Million in Third Round Financing

Black Duck Software Closes $12 Million in Third Round Financing

February 14, 2007

Software Compliance Management Visionary and Provider of Industry’s Most Widely Used Solutions Raises Funds to Power Global Expansion, Further Broaden Product Line

LS9

LS9 Launched to Create Renewable Petroleum(TM) Biofuels

LS9 Launched to Create Renewable Petroleum(TM) Biofuels

February 14, 2007

Academic and Industry Leaders Pursue Industrial Applications of Synthetic Biology

BG Medicine, Inc.

Critical Path Liver Toxicity Biomarker Study to Commence with Participation from Seven Pharmaceutical Companies

Critical Path Liver Toxicity Biomarker Study to Commence with Participation from Seven Pharmaceutical Companies

February 21, 2007

Pre-Clinical Study Aims to Predict Human Toxicity

Adnexus Therapeutics

Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds

Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds

February 26, 2007

Companies To Leverage Adnexus' Proprietary Adnectin-PROfusion Product Engine For Advanced Biologics

Princeton, NJ and Waltham, MA, February 26, 2007 -- Bristol-Myers Squibb Company (NYSE:BMY) and Adnexus Therapeutics today announced a worldwide strategic alliance to discover, develop and commercialize Adnectin-based therapeutics for important oncology-related targets.

Helicos BioSciences Corporation

Helicos BioSciences Files Registration Statement for Initial Public Offering of Common Stock

Helicos BioSciences Files Registration Statement for Initial Public Offering of Common Stock

February 28, 2007

CAMBRIDGE, MASS., February 28 /CNW/ - Helicos BioSciences Corporation today announced it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock. All of the shares to be offered will be sold by the company. The number of shares to be sold in the proposed offering and the offering price have not yet been determined.